Background: Although the incidence of breast cancer is lower in African-American women than in White women, African-American women have a decreased survival rate. The difference in survival rate may stem from poor endocrine therapy adherence, which increases breast cancer recurrence. Therefore, accessible and culturally sensitive interventions to increase endocrine therapy adherence are necessary. Objective: The purpose of this concurrent convergent mixed methods study was to provide further data to guide the development of the proposed culturally sensitive mHealth app, STORY+ for African-American women with breast cancer. Methods: We recruited 20 African-American women diagnosed with estrogen-positive breast cancer and currently prescribed...
Background: Differential use of endocrine therapy (ET) by race may contribute to breast cancer outco...
Background: Current clinical guidelines recommend that hormone receptor-positive breast cancer survi...
Breast cancer is the most commonly diagnosed non-skin cancer in women and the leading cause of death...
Background: There is a proliferation of lifestyle-oriented mobile technologies; however, few have ta...
Background: Oral endocrine therapy (ET) is an inexpensive and effective therapy for hormone receptor...
Adjuvant endocrine hormonal therapy (EHT) is highly effective and appropriate for nearly all breast ...
PURPOSE: Oral anti-cancer medications are increasingly common and endocrine therapies represent the ...
Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer s...
Objective: Latina breast cancer survivors (BCS) report more symptom burden and poorer health-related...
Medication adherence is a major problem in oncology, specifically regarding hormonal therapies for b...
The aims of this study were to 1) describe endocrine therapy (ET) non-initiation, non-adherence, and...
We examined the current literature to understand factors that influence endocrine therapy (ET) adher...
Background. Adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years after treatment f...
Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibi...
Background: Latina breast cancer survivors experience poorer health-related quality of life (HRQoL),...
Background: Differential use of endocrine therapy (ET) by race may contribute to breast cancer outco...
Background: Current clinical guidelines recommend that hormone receptor-positive breast cancer survi...
Breast cancer is the most commonly diagnosed non-skin cancer in women and the leading cause of death...
Background: There is a proliferation of lifestyle-oriented mobile technologies; however, few have ta...
Background: Oral endocrine therapy (ET) is an inexpensive and effective therapy for hormone receptor...
Adjuvant endocrine hormonal therapy (EHT) is highly effective and appropriate for nearly all breast ...
PURPOSE: Oral anti-cancer medications are increasingly common and endocrine therapies represent the ...
Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer s...
Objective: Latina breast cancer survivors (BCS) report more symptom burden and poorer health-related...
Medication adherence is a major problem in oncology, specifically regarding hormonal therapies for b...
The aims of this study were to 1) describe endocrine therapy (ET) non-initiation, non-adherence, and...
We examined the current literature to understand factors that influence endocrine therapy (ET) adher...
Background. Adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years after treatment f...
Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibi...
Background: Latina breast cancer survivors experience poorer health-related quality of life (HRQoL),...
Background: Differential use of endocrine therapy (ET) by race may contribute to breast cancer outco...
Background: Current clinical guidelines recommend that hormone receptor-positive breast cancer survi...
Breast cancer is the most commonly diagnosed non-skin cancer in women and the leading cause of death...